Responses
Regular and young investigator award abstracts
Clinical trials in progress
379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor
Compose a Response to This Article
Other responses
No responses have been published for this article.
